Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. (Q34798892)
scientific article
Language:
(P31) (Q13442814)
(P50) (Q37834810)
(Q62089079)
(Q131901395)
(P304) 4563-4571
(P407) (Q1860)
(P433) 28
(P478) 26
(P577) Monday, July 21, 2008
(P921) (Q5452194)
(Q27888393)
(Q181257)
(P1433) (Q400292)
(P1476) "Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven" (language: en)
(P2093) Alison H M Reid
Timothy A Yap
Sarah Settatree
Mary Barrett
Christopher Parker
Vanessa Martins
Elizabeth Folkerd
Jeremy Clark
Colin S Cooper
David Dearnaley
Gloria Lee
Johann S de Bono
Mitch Dowsett
other details
description scientific article

External Links